U.S. Markets
Pfizer (PFE) announces positive topline results from a Phase 3 LITFULO study with patients with nonsegmental vitiligo
StockNow breaking-news AI analysis
Pfizer reported positive Phase 3 results for LITFULO in vitiligo, positioning the drug to compete with AbbVie’s Rinvoq and Incyte’s Opzelura in the growing oral JAK inhibitor market.
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.